Belumosudil for chronic graft-versus-host disease (CGVHD) after 2 or more prior lines of therapy: The rockstar study (KD025-213)

Authors
Category Primary study
ConferenceBlood
Year 2020
This article has no abstract
Epistemonikos ID: cab5f4d699468e068d7d8348fa2bfcf346514f85
First added on: Feb 12, 2025